Pharmaceutical Crisis: Is Israel Losing Access to New Medications?
A new crisis is currently unfolding within the Israeli healthcare system, sparking significant concern among experts and citizens alike. According to recent reports, multinational pharmaceutical companies are scaling back their operations in Israel, leading to significant delays in bringing new and advanced medications to the local market.
Kobi Tzuruf, CEO of "Pharma Israel," an organization representing 21 international pharmaceutical companies, warns that the current situation could negatively impact the quality of medical care in Israel. According to him, these companies are not only delaying the marketing of drugs but are also cutting the research and development budgets they invest within the country.
The reasons for this reduction in activity are complex, but they reflect a worrying trend of global companies exiting the Israeli market. As these companies reduce their presence, Israeli patients are forced to wait longer to receive life-saving treatments that are immediately available in other countries around the world.
The consequences of this crisis could be far-reaching, as the healthcare system relies heavily on collaborations with these companies. Without investments in local research and development, Israel risks losing its status as a leading medical and technological hub, which would hinder medical innovation in the long term.
As of now, professionals at the Ministry of Health are examining ways to address the situation and encourage companies to continue their operations in Israel. The Israeli public is waiting to see if a solution will be found that ensures quick and convenient access to essential medications for everyone who needs them.